People Category: Board of Directors

Thomas joined Novo A/S in 2000. He is a member of the Boards of Directors of Allievex Inc. and Anokion SA. Continue reading “Thomas Dyrberg, MD”

Patricia L. Allen brings over 20 years of financial and operations leadership experience at both publicly traded and private biotechnology companies.

Continue reading “Patricia L. Allen”

Dr. Laura Brass is a Managing Director at NVF in Cambridge, MA, USA. Prior to joining NVF, Laura was a Managing Director at MPM Capital, and prior to that, she was a member of the founding management team and SVP of Business Development for TriNetX, a healthcare IT company focusing on big data analytics of live patient data for clinical research.  Continue reading “Laura Brass, PhD, MBA”

Harry Welten, MBA, spent more than twenty years in international senior executive functions, sixtee of which as chief financial officer in biotechnology companies (privately as well as publicly held). Continue reading “Harry Welten”

Dhaval is a physician scientist who serves as an Executive Vice President and Chief Scientific Officer at Sana Biotechnology, and on the Boards of Directors for several biotech companies.
Continue reading “Dhavalkumar Patel, MD, PhD”

Jeff is a professor and founder of the Institute of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne (Swiss Federal Institute of Technology, EPFL), and a professor at the Institute of Molecular Engineering at the University of Chicago. Continue reading “Jeffrey Hubbell, PhD”

Nilesh has been with Novo Ventures (US) Inc. in Boston since 2015. Continue reading “Nilesh Kumar, PhD”

For 20 years, he has held various positions in the intellectual property and venture areas at Nestlé, Pasteur Mérieux Connaught (now Sanofi Pasteur) and Novartis. Continue reading “Florent Gros”

Robin Praeger CPA (inactive) is an advisor for Versant Ventures. Robin served as Versant’s CFO from 2000 to 2022. He was promoted to Managing Director in 2005.
Continue reading “Robin Praeger, CPA”

Dr. Clayman is a co-founder of Flexion Therapeutics and served as its President, Chief Executive Officer, and as a director from its inception in 2007 to its acquisition by Pacira Biosciences in 2021. Continue reading “Mike Clayman, MD”